Loading…
Loading…
ILMN does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for ILMN and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for ILMN and 80,000+ other tickers.
See exactly how ILMN's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ILMN and 80,000+ other tickers.
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They…
Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Illumina (ILMN) is rated a Buy, driven by robust demand for consumables and NovaSeq X instruments, supported by favorable market dynamics and regulatory tailwinds. NovaSeq X accounts for 59% of consumable revenues, up from 44% in Q2'25, highlighting strong uptake and positioning ILMN to capture expanding diagnostic consumables market share. Management guides for FY2026 revenue of $4.60–$4.64 billion and analysts expect EPS of $5.36, reflecting double-digit upside with a fair forward P/S target of 9.75x ($293.77).
Illumina's Q3 results may benefit from strong clinical demand, NovaSeq X adoption, instrument placements and innovations despite persistent weakness in research markets.
DRAGEN Ultra, BioInsight Platform Workflow Orchestrator, and BioInsight Platform Learning Cohorts are now available in early access, incorporating new AI-driven approaches to analysis, automation, and discovery The tools automate end-to-end informatics processes at scale and help customers build private data lakes to drive scientific and clinical research insights SAN DIEGO, Oct. 21, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today introduced three early-access capabilities on its BioInsight Platform that help researchers move faster from sequencing data to discovery. BioInsight Platform Workflow Orchestrator enables laboratories to operate consistent, traceable sequencing and informatics operations at scale.
SAN DIEGO, Oct. 20, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that members of its management team will participate at the following investor conference: Upcoming Investor Conference UBS Global Healthcare Conference on November 10, 2026 The fireside chat is scheduled for 07:15am PT (10:15am ET). The webcast can be accessed through the Events & Presentations section of Illumina's website at investor.illumina.com.